Key factors influencing multidrug-resistant tuberculosis in patients under anti-tuberculosis treatment in two centres in Burundi: a mixed effect modelling study

被引:7
|
作者
Iradukunda, Arnaud [1 ,2 ,3 ]
Ndayishimiye, Gabin-Pacifique [2 ]
Sinarinzi, Darlene [2 ]
Odjidja, Emmanuel Nene [3 ,4 ]
Ntakaburimvo, Nestor [2 ]
Nshimirimana, Innocent [1 ]
Izere, Cheilla [5 ]
机构
[1] Univ Burundi, Dept Med, PB 1550, Bujumbura, Burundi
[2] Lake Tanganyika Univ, Dept Stat, PB 5304, Mutanga, Burundi
[3] Royal Soc Trop Med & Hyg, 303-306 High Holborn, London, England
[4] Monash Univ, Sch Clin Sci, Dept Med, Wellington Rd, Clayton, Vic 3800, Australia
[5] Clermont Auvergne Univ, Dept Comp Math, PB 63000, Clermont Ferrand, France
关键词
Tuberculosis; Multidrug resistant tuberculosis; Bayesian; Bootstrap; Burundi; RISK-FACTORS; ADDIS-ABABA; PREVALENCE; EPIDEMIOLOGY; DETERMINANTS; SELECTION; ETHIOPIA; PROGRESS; 1ST;
D O I
10.1186/s12889-021-12233-2
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Despite the World Health Organization efforts to expand access to the tuberculosis treatment, multidrug resistant tuberculosis (MDR-TB) remains a major threat. MDR-TB represents a challenge for clinicians and staff operating in national tuberculosis (TB) programmes/centres. In sub-Saharan African countries including Burundi, MDR-TB coexists with high burden of other communicable and non-communicable diseases, creating a complex public health situation which is difficult to address. Tackling this will require targeted public health intervention based on evidence which well defines the at-risk population. In this study, using data from two referral anti-tuberculosis in Burundi, we model the key factors associated with MDR-TB in Burundi. Methods A case-control study was conducted from 1(st)August 2019 to 15(th) January 2020 in Kibumbu Sanatorium and Bujumbura anti-tuberculosis centres for cases and controls respectively. In all, 180 TB patients were selected, comprising of 60 cases and 120 controls using incidence density selection method. The associated factors were carried out by mixed effect logistic regression. Model performance was assessed by the Area under Curve (AUC). Model was internally validated via bootstrapping with 2000 replications. All analysis were done using R Statistical 3.5.0. Results MDR-TB was more identified among patients who lived in rural areas (51.3%), in patients' residence (69.2%) and among those with a household size of six or more family members (59.5%). Most of the MDR-TB cases had already been under TB treatment (86.4%), had previous contact with an MDR-TR case (85.0%), consumed tobacco (55.5%) and were diabetic (66.6 %). HIV prevalence was 32.3 % in controls and 67.7 % among cases. After modelling using mixed effects, Residence of patients (aOR= 1.31, 95%C: 1.12-1.80), living in houses with more than 6 family members (aOR= 4.15, 95% C: 3.06-5.39), previous close contact with MDR-TB (aOR= 6.03, 95% C: 4.01-8.12), history of TB treatment (aOR= 2.16, 95% C: 1.06-3.42), tobacco consumption (aOR = 3.17 ,95% C: 2.06-5.45) and underlying diabetes' ( aOR= 4.09,95% CI = 2.01-16.79) were significantly associated with MDR-TB. With 2000 stratified bootstrap replicates, the model had an excellent predictive performance, accurately predicting 88.15% (95% C: 82.06%-92.8%) of all observations. The coexistence of risk factors to the same patients increases the risk of MDR-TB occurrence. TB patients with no any risk factors had 17.6% of risk to become MDR-TB. That probability was respectively three times and five times higher among diabetic and close contact MDR-TB patients. Conclusion The relatively high TB's prevalence and MDR-TB occurrence in Burundi raises a cause for concern especially in this context where there exist an equally high burden of chronic diseases including malnutrition. Targeting interventions based on these identified risk factors will allow judicious channel of resources and effective public health planning.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen
    Babalik, Aylin
    Balikci, Ahmet
    Turkar, Ayla
    Teke, Nazli Huma
    Demir, Fatma Kubra
    Yavuz, Simge
    Koc, Emine Nur
    Gunduz, Senem
    Ergec, Buesra
    Alagoz, Hasan Can
    Sarioglu, Eren
    Kilicaslan, Zeki
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2024, 13 (03) : 265 - 274
  • [42] Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis
    Shen, Hongbo
    Yang, Enzhuo
    Guo, Ming
    Yang, Rui
    Huang, Guixian
    Peng, Ying
    Sha, Wei
    Wang, Feifei
    Shen, Ling
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 1790 - 1805
  • [43] Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study
    Mollel, Edson
    Lekule, Isack
    Lynen, Lutgarde
    Decroo, Tom
    INTERNATIONAL HEALTH, 2019, 11 (06): : 520 - 527
  • [44] Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
    Andrew J Nunn
    ID Rusen
    Armand Van Deun
    Gabriela Torrea
    Patrick PJ Phillips
    Chen-Yuan Chiang
    S Bertel Squire
    Jason Madan
    Sarah K Meredith
    Trials, 15
  • [45] High Incidence of Psychiatric Disorders Associated with Cycloserine Treatment of Multidrug-Resistant Tuberculosis Patients: A Cohort Study in Beijing, China
    Pang, Yu
    Liu, Rongmei
    Song, Yanhua
    Lv, Zizheng
    Gao, Mengqiu
    Nie, Lihui
    Ge, Qiping
    Wu, Xiaoguang
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 3725 - 3732
  • [46] Factors Associated with Non-Adherence for Prescribed Treatment in 201 Patients with Multidrug-Resistant and Rifampicin-Resistant Tuberculosis in Anhui Province, China
    Zhu, Qing-Qing
    Wang, Jie
    Sam, Napoleon Bellua
    Luo, Jie
    Liu, Jie
    Pan, Hai-Feng
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [47] Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
    Nunn, Andrew J.
    Rusen, I. D.
    Van Deun, Armand
    Torrea, Gabriela
    Phillips, Patrick P. J.
    Chiang, Chen-Yuan
    Squire, S. Bertel
    Madan, Jason
    Meredith, Sarah K.
    TRIALS, 2014, 15
  • [48] The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review
    Harris, Rebecca C.
    Grandjean, Louis
    Martin, Laura J.
    Miller, Alexander J. P.
    Nkang, Joseph-Egre N.
    Allen, Victoria
    Khan, Mishal S.
    Fielding, Katherine
    Moore, David A. J.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [49] The effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic review
    Rebecca C. Harris
    Louis Grandjean
    Laura J. Martin
    Alexander J. P. Miller
    Joseph-Egre N. Nkang
    Victoria Allen
    Mishal S. Khan
    Katherine Fielding
    David A. J. Moore
    BMC Infectious Diseases, 16
  • [50] Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China
    Zhu, Yue
    Forsman, Lina Davies
    Chen, Cheng
    Zhang, Haoyue
    Shao, Ge
    Wang, Sainan
    Wang, Shanshan
    Xiong, Haiyan
    Bruchfeld, Judith
    Wang, Weibing
    Zhu, Limei
    Alffenaar, Jan-Willem
    Hu, Yi
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (02) : 524 - 533